SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome ...

Earlier this week at the 2023 Detroit Auto Show, General Motors officially unveiled the all-new, next-generation 2024 GMC Acadia, which will go on sale in the U.S. in early 2024. Now, The General has ...

ACADIA Pharmaceuticals, Inc. (ACAD) Enters Agreement with Biovail Laboratories Inc. to Conclude Collaboration and Regain North American Rights to Pimavanserin; Acadia Receives $8.75 Million SAN DIEGO- ...

Gaspereau Press co-founders Andrew Steeves and Gary Dunfield have donated the full working archives of the press – from its inception to the present day – to their alma mater, Acadia University in ...

--DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...